IMMUNITYBIO INC (IBRX)
US45256X1037 - Common Stock
IBRX Stock Earnings: ImmunityBio Misses EPS, Beats Revenue for Q1 2024
IBRX stock results show that ImmunityBio missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
The 3 Best Bargain Stocks to Buy in May 2024
There are several types of bargain stocks for investors to consider. Here are the three best bargain stocks to buy now.
ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®
Even Worse than Gamestop? 3 Meme Stocks That Are Screaming Sells
Here are just a few of the top meme stocks to sell immediately. In fact, I wouldn't waste investment dollars on any.
Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050
/PRNewswire/ -- USA News Group – An alarming trend is happening around the world, where tens of millions of progressively younger people are being diagnosed...
Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050
/CNW/ -- USA News Group – An alarming trend is happening around the world, where tens of millions of progressively younger people are being diagnosed with of...
Monday's session: most active stocks
These stocks are making the most noise in today's session. Stay tuned for the latest updates!
What’s going on with the ImmunityBio (IBRX) stock price?
ImmunityBio (NASDAQ: IBRX) stock price has gone parabolic as investors cheer the recent approval of Anktiva, its cancer drug. It has risen for two straight days and is now sitting at its highest level since September 2021. It is up by over 770% from its lowest point in 2023, giving it a market cap of […]
The market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session.
These stocks are gapping in today's session
Interesting IBRX Put And Call Options For June 7th
Noteworthy Tuesday Option Activity: IBRX, BKNG, UPST
FDA Approves ImmunityBio's Bladder Cancer Drug, Stock Rallies
Monday, the FDA approved ImmunityBio Inc’s (NASDAQ:IBRX) Anktiva (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. The drug is combined with the BCG vaccine, mainly used against tuberculosis and as a common treatment for some forms of bladder cancer. Last year in May, the FDA issued a complete response letter to Anktiva plus BCG treatment
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're diving into the biggest pre-market stock movers that traders are going to want to keep an eye on for Tuesday morning!
Here’s why ImmunityBio (IBRX) stock price surged and what next
ImmunityBio (NASDAQ: IBRX) stock price resumed its strong rally this week after the company achieved a major milestone. After dropping by over 6% in the regular session on Monday, it rebounded by over 20% in the extended session. FDA approves ANKTIVA This rally makes ImmunityBio one of the best-performing stocks in Wall Street as it […]
Commit To Purchase ImmunityBio At $2.50, Earn 26.7% Annualized Using Options
IBRX Stock Earnings: ImmunityBio Misses EPS, Beats Revenue for Q4 2023
IBRX stock results show that ImmunityBio missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
IBRX Stock Earnings: ImmunityBio Misses EPS, Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips ImmunityBio (NASDAQ:IBRX) just reported results for the fourth quarter of 2023....